Three recent studies show that modifying gut microbiota with faecal microbiota transplantation (FMT) is feasible in patients treated with immune-checkpoint inhibitors in the first-line setting. This expands the growing evidence that microbiota modulation can augment responses to ICIs.
The report discusses opportunities to refine these approaches to improve the rigor and potential clinical benefit of microbiota modulation trials in oncology. If data are incomplete in the source, uncertainty is noted: the brief indicates feasibility and potential to enhance ICI response but does not provide detailed outcomes, patient selection criteria, specific microbial taxa implicated, dosing regimens, scheduling with ICIs, safety events, or long-term follow-up.
The emphasis is on methodological refinement to strengthen future trials, rather than presenting definitive efficacy or practice-changing conclusions. In clinical context, these findings underscore the need for standardized trial designs, robust endpoints, and careful monitoring when integrating FMT with first-line immunotherapy.
Nature Reviews Clinical Oncology published a clinical update in Oncology on 09 Apr 2026.
The item focuses on Cultivating the microbiome to enhance cancer immunotherapy.
Review the original article for the full source wording and details.